Mårten Fernö

14.1k citations

232 papers · 10.0k indexed · 2 hit papers · h-index 52

Oncology top 0.2%
Cancer Research top 0.2%
Molecular Biology top 1%
Pulmonary and Respiratory Medicine top 1%
Genetics top 1%

Co-authors: Åke Borg Pär‐Ola Bendahl Bo Baldetorp Håkan Olsson Lisa Rydén Kristina Lövgren D. Killander Markus Ringnér
Topics: Breast Cancer Treatment Studies (92 papers)HER2/EGFR in Cancer Research (54 papers)Estrogen and related hormone effects (53 papers)
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Nature Medicine
Partner nations: Sweden United States Germany

In The Last Decade

Mårten Fernö

230 papers receiving 9.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Molecular Taxonomy for Urothelial Carcinoma

2012 637 citations Gottfrid Sjödahl, Martin Lauss et al. Clinical Cancer Research profile →
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.

2001 540 citations Markus Ringnér, Lao H. Saal et al. PubMed profile →

Peers

Countries citing papers authored by Mårten Fernö

Since Specialization

Citations

This map shows the geographic impact of Mårten Fernö's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mårten Fernö with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mårten Fernö more than expected).

Fields of papers citing papers by Mårten Fernö

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mårten Fernö. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mårten Fernö. The network helps show where Mårten Fernö may publish in the future.

Co-authorship network of co-authors of Mårten Fernö

This figure shows the co-authorship network connecting the top 25 collaborators of Mårten Fernö. A scholar is included among the top collaborators of Mårten Fernö based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mårten Fernö. Mårten Fernö is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer 2023 ·Journal of Clinical Oncology ·Martin Sjöström,Anthony Fyles,Fei‐Fei Liu,David R. McCready,Wei Shi,(unknown),S. Laura Chang,Felix Y. Feng,Corey Speers,Lori J. Pierce,Erik Holmberg,Mårten Fernö,Per Malmström,Per Karlsson	21
2	St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study 2021 ·British journal of surgery ·(unknown),(unknown),Mårten Fernö,Christian Ingvar,(unknown),Lisa Rydén	4
3	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy 2019 ·Clinical Cancer Research ·Martin Sjöström,S. Laura Chang,Nick Fishbane,Elai Davicioni,Linda Hartman,Erik Holmberg,Felix Y. Feng,Corey Speers,Lori J. Pierce,Per Malmström,Mårten Fernö,Per Karlsson	12
4	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients 2017 ·Clinical Cancer Research ·Nicholas P. Tobin,Arian Lundberg,Linda S. Lindström,J. Chuck Harrell,Theodoros Foukakis,Lena Carlsson,Zakaria Einbeigi,Barbro Linderholm,Niklas Loman,Martin Malmberg,Mårten Fernö,Kamila Czene,Charles M. Perou,Jonas Bergh,Thomas Hatschek	10
5	Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance 2015 ·Cancer Research ·Susann Busch,Andrew H. Sims,Olle Stål,Mårten Fernö,Göran Landberg	22
6	Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer 2015 ·Clinical Cancer Research ·Siker Kimbung,Ida Johansson,Anna Danielsson,Srinivas Veerla,Søren Brage,Marianne Frostvik Stolt,Lambert Skoog,Lena Carlsson,Zakaria Einbeigi,Elisabet Lidbrink,Barbro Linderholm,Niklas Loman,Per-Olof Malmström,Martin Söderberg,Thomas Walz,Mårten Fernö,Thomas Hatschek,Ingrid Hedenfalk	36
7	The role of histological grade in discrimination between Luminal A-like and Luminal B-like subtypes in a series of premenopausal breast cancer patients 2014 ·Lund University Publications (Lund University) ·Anna Ehinger,Pär‐Ola Bendahl,C.W. Elston,Per Malmström,Dorthe Grabau,Mårten Fernö	2
8	G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients 2013 ·Clinical Cancer Research ·Stefan Broselid,Benxu Cheng,Martin Sjöström,Kristina Lövgren,(unknown),Mattias Belting,Karin Jirström,Per Malmström,Björn Olde,Pär‐Ola Bendahl,Linda Hartman,Mårten Fernö,L.M. Fredrik Leeb-Lundberg	35
9	Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up 2013 ·Breast Cancer Research and Treatment ·(unknown),Pär‐Ola Bendahl,Gunilla Chebil,Hans Olsson,Mårten Fernö,Lisa Rydén	47
10	The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer 2013 ·PLoS ONE ·Marie Klintman,Carina Strand,Cecilia Ahlin,(unknown),Marie-Louise Fjällskog,Dorthe Grabau,Einar Gudlaugsson,Emiel A. M. Janssen,Kristina Lövgren,Ivar Skaland,Pär‐Ola Bendahl,Per Malmström,Jan P. A. Baak,Mårten Fernö	24
11	A Molecular Taxonomy for Urothelial Carcinomabreakdown → 2012 ·Clinical Cancer Research ·Gottfrid Sjödahl,Martin Lauss,Kristina Lövgren,Gunilla Chebil,Sigurður Guðjónsson,Srinivas Veerla,Oliver Patschan,Mattias Aine,Mårten Fernö,Markus Ringnér,Wiking Månsson,Fredrik Liedberg,David Lindgren,Mattias Höglund	637
12	Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1 2010 ·Cancer Research ·Jeanette Nilsson,Khalil Helou,Anikó Kovács,Pär‐Ola Bendahl,Gunnar Bjursell,Mårten Fernö,Peter Carlsson,Marie Kannius‐Janson	58
13	Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer – A national survey performed at pathology departments in Sweden 2009 ·Acta Oncologica ·Lisa Rydén,(unknown),Pär‐Ola Bendahl,Thomas Hatschek,(unknown),Anikó Kovács,(unknown),Hans Olsson,Carina Strand,Mårten Fernö,(unknown)	23
14	Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma 2007 ·Clinical Cancer Research ·Sofia K. Gruvberger-Saal,Pär‐Ola Bendahl,Lao H. Saal,Mervi Laakso,Cecilia Hegardt,P. Edén,Carsten Peterson,Per Malmström,Jorma Isola,Åke Borg,Mårten Fernö	154
15	Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail? 2007 ·Urologic Oncology Seminars and Original Investigations ·Fredrik Liedberg,Harald Anderson,Gunilla Chebil,Sigurður Guðjónsson,Mattias Höglund,David Lindgren,(unknown),Kristina Lövgren,Mårten Fernö,Wiking Månsson	28
16	Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles 2004 ·Molecular Cancer Therapeutics ·Sofia K. Gruvberger-Saal,Patrik Edén,Markus Ringnér,Bo Baldetorp,Gunilla Chebil,Åke Borg,Mårten Fernö,Carsten Peterson,Paul S. Meltzer	25
17	Flow cytometric S-phase fraction in soft-tissue sarcoma: prognostic importance analysed in 160 patients 1997 ·British Journal of Cancer ·Pelle Gustafson,Mårten Fernö,Måns Åkerman,Bo Baldetorp,Helena Willén,D. Killander,Anders Rydholm	17
18	HER-2/neu amplification predicts poor survival in node-positive breast cancer. 1990 ·PubMed ·Åke Borg,Amol Tandon,Helgi Sigurðsson,Gary M. Clark,Mårten Fernö,Suzanne A.W. Fuqua,D. Killander,(unknown)	393
19	Enzyme immunoassay of progesterone receptor in cancerous and normal endometrial tissue. A comparison with dextran coated charcoal method. 1989 ·PubMed ·Mårten Fernö,Alexander Borg,Gy. Horváth,B Lindahl	2
20	Estrogen receptor activation in relation to previous estrogen treatment in carcinoma corporis uteri heterotransplanted into nude mice. 1989 ·PubMed ·G. Horváth,Mårten Fernö,(unknown),Jonas Ranstam	4

About Mårten Fernö

Mårten Fernö is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 232 papers that have together received 10.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (92 papers), HER2/EGFR in Cancer Research (54 papers) and Estrogen and related hormone effects (53 papers). The work is most often cited by research in Cancer Research (4.1k citations), Oncology (4.9k citations) and Pathology and Forensic Medicine (1.3k citations). Mårten Fernö has collaborated with scholars based in Sweden, United States and Germany. Frequent co-authors include Åke Borg, Pär‐Ola Bendahl, Bo Baldetorp, Håkan Olsson, Lisa Rydén, Kristina Lövgren, D. Killander, Markus Ringnér, Helgi Sigurðsson and Lao H. Saal. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact